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Abstract
Introduction: N-3 Polyunsaturated fatty acids (n-3 PUFA) exert clinical beneficial
effects in patients after acute myocardial infarction (AMI). However, their exact
mechanisms of action are not well recognized yet. Our aim was to evaluate
effects of early introduced n-3 PUFA supplementation on endothelial function
and serum adipokine concentrations in patients with AMI.
Material and methods: Thirty-eight patients with AMI and successful coronary
stent implantation were randomized to the study group (PUFA group: n = 19;
standard therapy + PUFA 1 g daily) and the control group (control group: n = 19;
standard therapy). The study group patients were given n-3 PUFA (Omacor 1 g
daily) starting from the 3rd day of AMI. Ultrasound vascular indexes (flow-
mediated dilatation [FMD], nitroglycerine-mediated dilation [NMD]) and serum
concentrations of adiponectin and resistin (ELISA) were evaluated before and
after 30 days of pharmacotherapy. 
Results: Comparison of the mean delta values (baseline/after 30 days of therapy)
between groups revealed significant differences for delta FMD (PUFA 7.6 ±12.4%
vs. control –1.7 ±10.5%, p = 0.019) and delta resistin concentrations (PUFA 1.0
±3.8 pg/ml vs. control –1.6 ±2.9 pg/ml, p = 0.028). Multiple linear regression
analysis for all subjects revealed the n-3 PUFA supplementation (r = 10.933, 
p = 0.004) and waist circumference (r = –0.467, p = 0.01) as independent factors
associated with delta FMD values (R-adjusted 0.29; p = 0.002).
Conclusions: Early and short-term n-3 PUFA supplementation in AMI with
successful primary PCI and optimal pharmacotherapy improves endothelial
function. However, increased resistin serum levels observed after 1-month n-3
PUFA supplementation merits further investigations. 
Key words: polyunsaturated fatty acids, adiponectin, resistin, endothelial function,
myocardial infarction.
Introduction
Numerous epidemiological and clinical studies have demonstrated that
n-3 polyunsaturated fatty acids (PUFA) – eicosapentaenoic (EPA) and
docosahexaenoic (DHA) acids – affect several cardiovascular endpoints with
significant clinical effects in patients after acute myocardial infarction (AMI)
[1, 2]. However, despite a large number of studies on n-3 PUFA use in
coronary artery disease (CAD), observations provided in an early phase of
AMI with potential preclinical effects and potential mechanisms responsibleArch Med Sci 5, October / 2011 789
for cardiovascular benefits are limited. The GISSI-
Prevenzione study showed that the early effects of
n-3 PUFA supplementation were statistically
significant after a 3-month period – patients were
enrolled in the study up to 3 months from an MI and
those benefits were based on clinical findings [1].
We might assume that some of the clinical effects
could have significantly improved earlier than after
3 months. This is especially important because
according to recently published data a short 
(1 month) n-3 PUFA therapy signi  ficantly potentiated
platelet response to clopidogrel after percutaneous
coronary intervention (PCI) [3]. Thus the issue of the
early pleiotropic effects of n-3 PUFA supplementation
is currently of high interest. 
Patients with acute coronary syndrome (ACS)
reveal numerous pathophysiological abnormalities,
including decreased nitric oxide (NO) bioavailability,
which is reflected in endothelial dysfunction [4]. In
the literature there are inhomogeneous data on 
n-3 PUFA intake and values of flow-mediated
dilatation (FMD) – an ultrasound non-invasive index
of endothelial function as well as an overall risk
factor reflecting future prognosis and therapeutic
interventions [5-7]. A significant improvement in
endothelial function after n-3 PUFA supple  -
mentation was observed in some primary pre  -
vention clinical studies with no effects after AMI,
which suggests the distinctiveness of n-3 PUFA
effects in different populations [7-9].
On the other hand, a growing body of evidence
suggests that adipose tissue is considered to be an
important organ that secretes adipokines and is
involved in the development of endothelial
dysfunction and cardiovascular and metabolic
diseases [10, 11]. N-3 PUFA supplementation may
potentially modify both the activities of both pro-
and anti-atherosclerotic adipokines. Adiponectin
constitutes the main anti-atherosclerotic adipokine,
and has a wide range of metabolic effects: it inhibits
hepatic gluconeogenesis, improves oxidation of
muscle fatty acids and insulin sensitivity, and
increases HDL cholesterol synthesis. Moreover,
adiponectin affects endothelial cells, reveals anti-
oxidative effects, suppresses the expression of
several proinflammatory cytokines and modulates
vascular remodelling [12-15]. Resistin is a relatively
new pro-atherosclerotic adipocyte-derived cytokine
that affects glucose and lipid metabolism, thereby
resulting in insulin resistance [13]. Experimental
studies provide incoherent observations on the final
cardioprotective or cardiodestructive role of resistin
in AMI [16]. 
We aimed to explore whether early initiated 
30-day n-3 PUFA therapy exerts an influence on
ultrasound endothelial function parameters, adipo  -
nectin and resistin serum levels in patients with AMI. 
Material and methods
Thirty-eight patients with AMI and successful
coronary stent implantation were included in the
study and randomly assigned to receive n-3 PUFA
(Omacor; 1 g/day omega-3-acid ethyl esters =
465 mg EPA + 375 mg DHA; Solvay Pharma,
Hanover, Germany) introduced from the 3rd day 
of AMI (PUFA group; n = 19; F/M = 5/14, age: 56 ±8
years; STEMI: 74%; TIMI 3: 100%; standard therapy
+ PUFA 1 g daily) or control group (control group; 
n = 19; F/M = 3/16; age: 62 ±9 years; STEMI: 58%;
TIMI 3: 100%; standard therapy). 
All patients were diagnosed with typical chest
pain, dynamic ST changes in the electrocardiogram,
a new regional wall motion abnormality in the
echocardiography and significantly increased cardiac
markers exceeding the 99th percentile of the upper
reference limit (URL) (CPK – creatine phospho  -
kinase, CPK-MB – creatine phosphokinase-myo  -
cardial bound isoenzyme, troponin I). 
The following ultrasound endothelial function
indices were obtained at the baseline (3rd day of
AMI) and after one month (30 ±1 days) of therapy:
brachial artery diameter (BAd), FMD, NMD and
serum levels of adiponectin and resistin (ELISA). 
The pharmacotherapy given to all patients
(standard therapy) followed the European Society
of Cardiology (ESC) recommendations: 75/100 mg
acetylsalicylic acid, 75 mg clopidogrel, 40 mg
atorvastatin, a β-blocker and angiotensin-converting
enzyme inhibitors (ACE-I) adjusted to heart rate and
blood pressure (Table I). 
None of the participants had been taking any n-
3 PUFA or other PUFA medications before. All
patients declared ≤ 1 fish meal weekly in the past.
Drug PUFA group  Control Value of p
(n-3 PUFA) group
(N = 19) (N = 19)
No. (%) No. (%)
Acetylsalicylic acid 19 (100%) 19 (100%) NS
Clopidogrel 19 (100%) 19 (100%) NS
Atorvastatin 19 (100%) 19 (100%) NS
β-Adrenolytics 19 (100%) 19 (100%) NS
Angiotensin-  19 (100%) 19 (100%) NS
converting
enzyme inhibitors
Diuretics 9 (47%) 7 (37%) NS
Dihydropyridine  2 (11%) 4 (22%) NS
calcium channel 
blockers
Table I. Pharmacotherapy in study groups
Data are expressed as mean ± SD and as medians for abnormally
distributed variables
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Compliance with the study drug (Omacor)
supplementation was determined by a capsule
count and patients’ reports and all individuals
included in the PUFA group ingested all doses as
instructed before the study. 
The exclusion criteria included the following:
acute and chronic inflammatory diseases (in the
preceding 3 months), cigarette smoking within 12 h
before examination, 2nd and 3rd degree hyper  -
tension according to ESC guidelines, history of acute
coronary syndrome or cerebral infarction within 
6 months prior to study enrolment, history of
coronary revascularization (percutaneous coronary
angioplasty or cardiosurgery), general surgery within
6 months prior to study enrolment, acute heart
failure within 6 months prior to study enrolment,
chronic heart failure, diabetes (previously diagnosed
and/or treated, newly diagnosed: clinical symptoms
of hyperglycaemia with casual plasma glucose 
≥ 200 mg/dl, fasting plasma glucose ≥ 126 mg/dl
or diabetes – 2-h plasma glucose ≥ 200 mg/dl in
oral glucose tolerance test performed if necessary),
obe  sity (defined as body mass index [BMI] 
> 35 kg/m2), acute or chronic inflammatory,
autoimmunological or infectious diseases, liver
dysfunction (alanine aminotransferase > 3 × URL,
bilirubin > 1.2 mg/dl), renal (Cockcroft-Gault
glomerular filtration rate < 60 ml/min) or pancreatic
(amylase > 1.5 × URL) dysfunction, gastrointestinal
tract disorders or psychological diseases in the
preceding 6 months hindering study participation
or affecting evaluated parameters. Additionally,
patients with a history of malignancies in the
preceding 5 years were excluded. Finally, individuals
with severe dyslipidaemia (total cholesterol ≥ 320
mg/dl or low density lipoprotein cholesterol ≥ 240
mg/dl, or triglycerides ≥ 400 mg/dl) requiring higher
doses of statins or combination pharmacotherapy
or uncontrolled arterial hypertension and prior 
long-term therapy with drugs with a potential
influence on adipokines (e.g. hypolipidaemic, ACE
inhibitors, angiotensin receptor antagonists, anti-
inflammatory, anti-infectious, immunomodulatory
drugs, hormone replacement therapy) were not
included. Patients with significant abnormalities in
laboratory tests defined as red blood cells < 4.2 
× 106/μl, haemoglobin < 12 g/dl, platelet count 
< 100 × 103/μl were excluded.
The clinical characteristics of patients consisted
of medical history (familial diseases, concomitant
diseases, pharmacotherapy used, dietary habits and
smoking status), physical examination, standard
laboratory tests (including lipidograms), adiponectin
and resistin serum concentration evaluation, 
and accessory investigations (electrocardiogram,
echocardiography). Echocardiography was perfor  -
med in all patients according to the standards of
the European Society of Echocardiography. 
All clinical data, accessory investigations,
adiponectin and resistin serum levels were
obtained at baseline (3rd day of AMI) and after 30
days of therapy. The ultrasound measurements
were performed in the morning after an overnight
fast and 12 h off hypertension medications and
smoking.
Subjects were recruited and completed the study
at the Department of Cardiology at the Medical
University of Silesia. The study protocol was
approved by the local Silesian University of
Medicine Ethics Committee and all individuals
submitted written informed consent for the study
procedures.
The following vascular ultrasonography techni  -
ques were used to assess the functional and
structural remodelling of the vascular system
Flow-mediated dilatation
Endothelium-dependent FMD was assessed
according to the standard techniques [17]. The
measurements of brachial artery FMD were done
in a quiet, temperature-controlled room, between
9 and 11 am. Patients were examined after at least
10-min rest; ultrasound examination was
performed in a supine position. Expert investi  -
gators took measurements in a B-mode presen  -
tation. The brachial artery of the dominant
forearm was visualized above the antecubital
fossa in a longitudinal plane, with a sphygmo  -
manometric cuff on the proximal part of the arm.
The BAd was described as a minimal distance
between “m” lines, from the anterior to posterior
wall of the artery. Images were acquired with an
ECG gating, with measurements made in end
diastole, which corresponds to the onset of the 
R wave. The study was performed in three stages:
1) stage 1: baseline BAd and flow measurements
were made, and an average was calculated for
each subject; 2) stage 2: sphygmomanometer cuff
was inflated to 200 mmHg to occlude arterial
inflow for 3 min; 3) stage 3: BAd and blood flow
were measured and the mean of the values
obtained during 50 to 60 s after cuff deflation was
calculated. Taking these two measurements into
consideration (baseline and after cuff deflation),
FMD was calculated (percent increase of the artery
diameter in comparison to baseline results). After
a 10-min rest, a sublingual tablet of nitroglycerine
(0.5 mg) was administered to determine the
maximum obtainable exogenous vasodilatory
response. The BAd and blood flow were measured
following NTG, and NMD was determined 
(NTG-induced percent increase of the artery
diameter). All FMD and NMD measurements were
performed blind to the treatment with intra- and
inter-observer variability in our lab < 8%.
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Blood sampling and laboratory measurements
Blood samples were collected from each subject
after a 10-h fast. After centrifugation, aliquots were
frozen at –80°C until assayed.
The measurements of adiponectin and resistin
concentration were performed by ELISA Kit (R&D
Systems, USA). Lipid parameters (total serum
cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides) were measured using commercially
available test kits (Point Scientific Inc. Michigan,
USA).
Statistical analysis
All text and table results are expressed as means
± standard deviation (SD) for normally and as
medians for abnormally distributed variables or
number and percentage. The results’ normal
distribution was analysed with the Kolmogorov-
Smirnov test. Baseline clinical parameters and the
results of accessory investigations were compared
using two-sample t-tests for normally distributed
continuous variables (Student’s t-test); in case of
non-normal distribution, the Mann-Whitney U test
was used. Wilcoxon test or paired samples t-test
was performed to evaluate the significance of
parameters’ changes over time. Spearman rank
model was used for correlation analysis of the
baseline parameters and the parameters obtained
after 30-day therapy. The Pearson model was used
to determine the relationships between the delta
values of the variables (baseline/after 30-day
therapy). To compare the change of adiponectin,
resistin, FMD and NMD over time, the data were
analysed as repeated measures analysis of variance,
taking into account intervention factors and time.
If the data were positively skewed, logarithmic
transformation was used. Multivariable linear
regression was used to assess independent
predictors of the FMD, NMD, adiponectin and
resistin concentrations as well as the delta values
of the variables. Variables related to the dependent
factor (p < 0.2) in a univariate analysis were tested
in a multiple regression analysis. If the correlation
coefficients between potentially independent
factors were beyond the interval –0.70 to 0.70, one
of them was excluded. A value p < 0.05 was
considered statistically significant.
Results
Baseline parameters
There were no significant differences between
the two groups in regard to demographic or clinical
characteristics (Table II) or pharmacotherapy used
(“Materials and Methods”, Table I).  
The PUFA and the control groups did not differ
significantly in baseline ultrasound vascular indexes:
BAd (PUFA – 4.2 ±0.4 mm vs. control – 4.3 ±0.7 mm;
p = ns), FMD (PUFA – 7.3 ±6.2% vs. control – 10.9
±6.5%; p = ns), NMD (PUFA – 24.5 ±13.9% vs. control
– 26.3 ±12.4%; p = ns) or baseline adiponectin 
(PUFA – median – 9.8 mg/ml vs. control – median –
9.1 mg/ml, p = ns) and resistin (PUFA – median – 
4.6 pg/ml vs. control – median – 7.0 pg/ml; p = ns)
serum levels (Table III). 
Outcome data – 30-day evaluation
There were no differences in the clinical
outcome after 30-day therapy between the two
Parameter PUFA  group Control Value of p
(n-3 PUFA) group
(N = 19) (N = 19)
Mean ± SD  Mean ± SD 
or No. (%) or No. (%)
Age [years] 56 ±8 62 ±10 NS
Female/male 5 (26%)/ 3 (19%)/ NS
14 (74%) 16 (81%) 
Weight [kg] 85 ±10 83 ±8 NS
Height [cm] 173 ±7 174 ±5 NS
Waist [cm] 102 ±9 101 ±7 NS
Hip [cm] 103 ±6 100 ±6 NS
BMI [kg/m2] 27.2 ±3.2 27.5 ±2.9 NS
TCh [mg/dl] 192.1 ±31.5 183.7 ±30.5 NS
TG [mg/dl] 136.4 ±43.7 128.9 ±47.3 NS
HDL [mg/dl] 43.4 ±15.4 44.5 ±18.6 NS
LDL [mg/dl] 125.3 ±31.5 113.7 ±29.0 NS
Creatinine [mg/dl] 0.89 ±0.23 0.96 ±0.24 NS
CK [U/l] 1320 ±726 942 ±630 NS
CK-MB [U/l] 153.5 ±105.1 106.4 ±68.4 NS
Troponin I [ng/ml] 8.4 ±7.6 8.5 ±6.3 NS
STEMI/NSTEMI 14 (74%)/ 11(58%)/
5 (26%) 8 (42%) NS
Anterior wall 6 (32%) 6 (32%) NS
Lateral wall 3 (16%) 3 (16%) NS
Inferior wall 8 (42%) 7 (37%) NS
Indeterminate 2 (11%) 3 (16%)  NS
Current smoking 10 (53%) 10 (53%) NS
Family history 5 (26%) 4 (22%) NS
Hypertension I 14 (74%) 16 (82%) NS
Hospitalization 6.0  ±1.7 5.8±1.4 NS
[days]
Table II. Baseline demographic and clinical characte  -
ristics of study patients
BMI – body mass index, TCh – total cholesterol, TG – triglycerides, 
HDL – high-density lipoprotein, LDL – low-density lipoprotein, 
CPK – creatinine phosphokinase, CPK-MB – creatinine phosphokinase
MB-isoenzyme, STEMI – ST-elevated myocardial infarction 
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groups. There were no sudden deaths or AMI in
either group during 30-day observation. Re-
hospitalization due to recurrent angina was
reported in 1 patient from the PUFA group and 
2 controls. Angina symptoms were comparable
between the groups (CCS 0-I).  
Ultrasound parameters of endothelial function
and adipokine serum levels after 30-day
therapy
Mean FMD (7.3 ±6.2 to 14.9 ±10.4%, p = 0.02),
but not NMD (24.5 ±13.9 to 29.1 ±13.8%, p = 0.16)
values increased significantly after 30-day therapy
with n-3 PUFA. The FMD and NMD values did not
change significantly among control patients (FMD:
10.9 ±6.5% to 9.1 ±7.9%, p = 0.48; NMD: 26.3
±12.4% to 25.8 ±15.0%, p = 0.87) (Figure 1). Finally,
the PUFA group patients revealed significantly
higher FMD values compared to the control group
patients after 30-day therapy (14.9 ±10.4% vs. 9.1
±7.9%; p = 0.03). Comparison of the mean delta
values (baseline/after 30-day therapy) for both
groups revealed significant differences only for delta
FMD (PUFA: 7.6 ±12.4% vs. control: –1.7 ±10.5%; 
95% CI of difference: 1.62 to 17.12; p = 0.019) 
(Figure 2). The mean delta values of NMD were
comparable for both groups (PUFA: 4.9 ±13.3% vs.
control: –0.6 ±14.5%, p = 0.273).
There were no significant differences between
adipokine serum levels measured at the baseline and
after 30-day therapy in the PUFA group. However,
a non-significant increase of adipokine levels was
noted (adiponectin by 12.8%: 12.5 ±7.8 to 14.1
±8.0 mg/ml, p = 0.55; resistin by 20.7%: 5.3 ±2.9 
to 6.4 ±4.0 pg/ml, p = 0.35). The control group
patients revealed bidirectional statistically significant
changes in serum concentrations of adipokines: 
60.3% adiponectin increase (12.1 ±9.7 mg/ml to 19.4
±12.7 mg/ml; p = 0.044) and 36.1% resistin decrease
(6.4 ±3.0 pg/ml to 4.7 ±2.4 pg/ml; p = 0.044). Finally,
the PUFA group revealed lower (of borderline
significance) adiponectin serum level compared to
the Control group after 30-day therapy (14.1 ±8.0
mg/ml vs. 19.4 ±12.7 mg/ml; p = 0.053) (Table III).
Comparison of the mean delta values (baseline/ after
30-day therapy) for both groups revealed significant
differences only for the delta resistin concentration
(PUFA: 1.0 ±3.8 pg/ml vs. control: –1.6 ±2.9 pg/ml; 95%
CI of difference: 0.33-4.99; p = 0.028) (Figure 3). The
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Figure 1. Mean FMD values at baseline and after 
30-day therapy in PUFA and control groups
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Figure 2. Mean delta FMD values in PUFA and control
groups
D
e
l
t
a
 
F
M
D
 
[
%
]
p = 0.019
Delta FMD
n-3 PUFA group  Control group  Value of p
Source of variance
Baseline 30-day Baseline 30-day  Intervention (I) Time (T) Interaction I xT
evaluation evaluation evaluation evaluation
FMD [%] 7.3 ±6.2 14.9 ±10.4 10.9 ±6.5 9.1 ±7.9 0.57 0.17 0.019
NMD [%] 24.5 ±13.9 29.1 ±13.8 26.3 ±12.4 25.8 ±15.0 0.69 0.39 0.27
Adiponectin 12.5 ±7.8 14.1 ±8.0 12.1 ±9.7 19.4 ±12.7 0.49 0.026 0.225
[mg/ml] Median: 9.8 Median: 9.1
Resistin 5.3 ±2.9 6.4 ±4.0 6.4 ±3.0 4.7 ±2.4 0.71 0.56 0.028
[pg/ml] Median:  4.6 Median: 7.0
FMD – flow-mediated dilatation, NMD – nitroglycerine-mediated dilatation
p = 0.02 p = 0.48
Table III. Mean FMD and NMD values and mean adiponectin and resistin serum levels at baseline and after 30-day
therapy – interaction of group and time
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mean delta values of adiponectin levels were
comparable for both groups (PUFA: 1.7 ±11.0 pg/ml vs.
control: 7.3 ±17.2 mg/ml, p = 0.296).
Analysis of the intervention (n-3 PUFA supple  -
mentation) and time revealed that n-3 PUFA
supplementation significantly increased FMD values
(p = 0.019) and resistin serum levels (p = 0.028).
Serum adiponectin levels significantly increased 
30 days after AMI regardless of n-3 PUFA therapy
(p = 0.026). 
Mean values of FMD, NMD and adipokine levels
as well as the interaction of intervention and time
are presented in Table III.
Statistical analysis
There were no significant correlations between
FMD, NMD, adipokine serum concentrations and
demographic, clinical or biochemical parameters.
In the PUFA group, delta adiponectin concentrations
correlated in a borderline significant manner to
delta FMD values (r = 0.463, p = 0.061) (Figure 4). 
Multiple linear regression analysis for all subjects
examined revealed the n-3 PUFA supplementation 
(r = 10.933, p = 0.004) and waist circumference 
(r = –0.467, p  = 0.01) as independent factors
associated with delta FMD values (R-adjusted 0.29;
p = 0.002).
Discussion
The major finding of our pilot randomized and
prospective study was the demonstration that early
introduced low dose n-3 PUFA supplementation on
top of standard medical therapy compliant with
current guidelines improves ultrasound vascular
indexes of endothelial function. On the other hand,
n-3 PUFA contributed to a significant increase 
in resistin serum levels. Adiponectin serum
concentrations increased after AMI regardless of 
n-3 PUFA therapy; however, the n-3 PUFA-induced
FMD improvement seemed to be related to changes
in the adiponectin level. On the other hand, control
patients subjected to standard pharmacotherapy
without n-3 PUFA supplementation did not reveal
any ultrasound endothelial function improvement.
The study population was homogeneous and
included AMI patients successfully treated with PCI
selected according to strict and numerous exclusion
criteria, burdened with a relatively low secondary
prevention risk. 
The improvement in FMD presented in our
study indicates the favourable effects of early n-3
PUFA therapy in AMI. This is of great clinical
importance because it suggests that n-3 PUFA
might lower cardiovascular risk. The persistent
decrease in FMD over the weeks following ACS has
been found to carry negative predictive value [5].
However, pathomechanisms underlying FMD
improvement in patients treated with n-3 PUFA are
unclear. Recent studies suggest several potential
expla  nations: decreased endothelium molecular
adhesion and proinflammatory cytokines,
circulating free fatty acid level changes [8],
modulation of cell membrane function [18] or
reduced oxygen-derived free radical formation by
endothelial cells [19]. In our observation, an
increase in FMD was independently associated
with n-3 PUFA inter  vention and negatively with
waist. We cannot conclude that abdominal obesity
modifies the effect of PUFA supplementation.
However, the presented study is the first
suggesting a negative relationship between n-3
PUFA induced improvement in FMD values and
a patient’s waist circumference – an indicator of
abdominal obesity. There have not been any
published data on intervention-induced FMD
changes in relation to obesity to date. In the
literature there are only data on the relationship
between obesity and FMD. According to some
studies, obesity as a cardiovascular risk factor is
associated with lower FMD and NMD [20]. However,
there are also findings that FMD values in women
with primary obesity were comparable to the values
observed in controls with a normal BMI [21].
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Figure 3. Mean delta serum resistin concentrations
in PUFA and control groups
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Figure 4. Correlation between delta adiponectin
concentrations and delta FMD values in PUFA group
(r = 0.463, p = 0.061)
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Adipokines evaluated in our study exerted
potentially opposite effects on the cardiovascular
system, endothelial function, and metabolic status,
which might play a role in the clinical effects of 
n-3 PUFA supplementation in AMI. As we mentioned
above, one important finding was that n-3 PUFA
supplementation contributed to an increase in
resistin levels. Additionally, we found that the serum
adiponectin concentration increased regardless of
the intervention. Moreover, a significant change in
the direct concentrations of serum adipokines was
noted in the control group. Interestingly, the AMI-
induced adipokine "reaction", which was not
modified by n-3 PUFA supplementation, was
bidirectional, with a significant increase of
adiponectin and a decrease in the resistin level. 
We would assume that our adipokine evaluations
on the 3rd and 30th day were affected by an 
AMI-induced acute phase reaction and numerous
pathophysiological abnormalities but the potential
influence was similar in both groups. 
Kojima et al. reported a significant decline of
plasma adiponectin concentrations in patients
hospitalized for AMI, with the lowest levels at 72 h
after AMI, followed by a gradual increase [14],
which was in accordance with our observations.
It was demonstrated that adiponectin permeates
to the subendothelial space and exerts anti-
atherosclerotic and tissue-repairing effects within
the vascular wall, which seems to explain lower
adiponectin concentrations in blood during acute
phase reactions [14]. Both adiponectin and resistin
have been demonstrated to follow opposite
serum level patterns in different CAD populations,
with the lowest adiponectin and highest resistin
serum levels in AMI subjects as compared to
respectively unstable angina and stable angina
patients [24, 25].
Available evidence on potential effects of n-3
PUFA on adipokine levels in AMI is limited. Patel et
al. found no significant influence of additional n-3
PUFA (1 g daily) supplementation on serum levels
of adipokines (adiponectin, leptin and tumour
necrosis factor α) in post-MI patients after 
3-month treatment. There was an opposite direction
of insulin fasting level changes during follow-up.
An increase of insulin fasting concentrations in the
n-3 PUFA group and decrease in the control group
[26] were observed, which add to incoherent data
of n-3 PUFA influence on insulin resistance in
different subpopulations [27]. Moreover, it has been
documented that resistin affected glucose and lipid
metabolism, resulting in insulin resistance [13]. Our
results showing a significant increase in resistin
levels and lower adiponectin levels in the PUFA
group may suggest an interesting explanation for
these observations. 
On the other hand, Micallef et al. demonstrated
a significant adiponectin level increase and tumour
necrosis factor alpha level decrease in hyper  -
lipidaemic individuals subjected to a combination
of n-3 PUFA and plant sterols supplementation,
suggesting a favourable influence on metabolically
active hormones in a different clinical setting [28]. 
Our potential limitation is a relatively small study
sample, which partly results from numerous
exclusion criteria. Nevertheless, we are presenting
a pilot study in a research area of limited data.
Finally, we measured adiponectin without distin  -
guishing weight molecular forms of adiponectin.
Our study did not document a distinct relation
between FMD and adipokines. Because in the PUFA
group delta adiponectin concentrations correlated
in a borderline significant manner with delta FMD
values, we might only hypothesize that FMD
improvement could be mediated by adiponectin.
On the other hand, the significant resistin changes
in the PUFA group modify adiponectin/resistin
balance; thus it should not be underemphasized
but needs further evaluation.
In conclusion, early and short-term n-3 PUFA
supplementation in AMI with successful primary
PCI and optimal pharmacotherapy improves
endothelial function assessed as FMD. Favourable
FMD effects of n-3 PUFA in AMI may be mediated
by adiponectin; however, its significant increase is
not specific to n-3 PUFA intervention but is
observed in all patients after AMI. An increase in
resistin serum levels found in the n-3 PUFA group
contributes to potential negative changes in
adiponectin and resistin balance and may affect
endothelial function. This finding merits further
investigations of its relationship to metabolic and
carbohydrate homeostasis. 
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